Redmile Group LLC 13D and 13G filings for Akero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 4:26 pm Sale |
2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Redmile Group LLC | 1,109,476 2.000% |
-1,523,436 (-57.86%) |
Filing |
| 2023-02-14 4:23 pm Purchase |
2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Redmile Group LLC | 2,632,912 5.600% |
1,030,627 (+64.32%) |
Filing |
| 2022-02-14 5:07 pm Sale |
2021-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Redmile Group LLC | 1,602,285 4.600% |
-720,272 (-31.01%) |
Filing |
| 2021-02-16 4:05 pm Purchase |
2020-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Redmile Group LLC | 2,322,557 6.690% |
2,322,557 (New Position) |
Filing |